These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 24160681

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K, Homann CN, Fabbrini G, Colosimo C.
    Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
    [Abstract] [Full Text] [Related]

  • 4. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Jul; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect.
    Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, Todorova A, Naidu Y, Tluk S, Chandiramani C, Martin A, Chaudhuri KR.
    J Parkinsons Dis; 2011 Jul; 1(2):197-203. PubMed ID: 23934921
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
    Sesar Á, Fernández-Pajarín G, Ares B, Rivas MT, Castro A.
    J Neurol; 2017 May; 264(5):946-954. PubMed ID: 28364292
    [Abstract] [Full Text] [Related]

  • 11. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ, Kulisevsky J.
    Rev Neurol; 2012 May; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
    Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, Di Rosa E, Martino G, Marconi R, La Spina P, Nicita-Mauro V, Di Rosa AE.
    Arch Gerontol Geriatr Suppl; 2004 May; (9):291-6. PubMed ID: 15207426
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 20. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR.
    Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.